China Shineway Pharmaceutical Group Limited (CSWYF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
China Shineway Pharmaceutical Group Limited (CSWYF) with AI Score 51/100 (Hold). China Shineway Pharmaceutical Group Limited focuses on the research, development, manufacture, and trade of Chinese medicines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026China Shineway Pharmaceutical Group Limited (CSWYF) Healthcare & Pipeline Overview
China Shineway Pharmaceutical Group Limited researches, develops, manufactures, and trades Chinese medicines, including modern formulations and TCM granules, targeting diverse therapeutic areas like cardio-cerebrovascular and pediatrics. Operating primarily in China and Hong Kong, the company distinguishes itself through a focus on traditional Chinese medicine within the broader healthcare sector.
Investment Thesis
China Shineway Pharmaceutical Group Limited presents a compelling investment case based on its established presence in the Chinese medicine market and its diversified product portfolio. With a P/E ratio of 7.38 and a profit margin of 24.8%, the company demonstrates strong profitability and efficient operations. The dividend yield of 5.52% offers an attractive income stream for investors. Key growth catalysts include increasing demand for traditional Chinese medicine and the company's expansion into new therapeutic areas. However, potential risks include regulatory changes in the pharmaceutical industry and competition from other drug manufacturers. The company's beta of 0.87 suggests lower volatility compared to the broader market. Investors may want to evaluate the company's financial stability, growth prospects, and risk factors before making an investment decision.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.76B indicates a substantial presence in the pharmaceutical market.
- P/E Ratio of 7.38 suggests the company may be undervalued compared to its earnings.
- Profit Margin of 24.8% demonstrates efficient operations and strong profitability.
- Gross Margin of 73.4% reflects the company's ability to manage production costs effectively.
- Dividend Yield of 5.52% provides an attractive income stream for investors.
Competitors & Peers
Strengths
- Established presence in the Chinese medicine market.
- Diversified product portfolio across multiple therapeutic areas.
- Strong gross margin of 73.4%.
- High profit margin of 24.8%.
Weaknesses
- Reliance on the Chinese market.
- Potential impact from regulatory changes in the pharmaceutical industry.
- Limited geographic diversification.
- Dependence on traditional Chinese medicine, which may face evolving consumer preferences.
Catalysts
- Ongoing: Increasing demand for traditional Chinese medicine in both domestic and international markets.
- Ongoing: Expansion of the company's product portfolio into new therapeutic areas.
- Upcoming: Potential regulatory approvals for new drug formulations.
- Ongoing: Strategic partnerships and collaborations with other pharmaceutical companies.
- Ongoing: Government support for the development of the pharmaceutical industry in China.
Risks
- Potential: Regulatory changes in the pharmaceutical industry could impact the company's operations.
- Potential: Competition from other pharmaceutical companies may erode market share.
- Potential: Pricing pressures and reimbursement challenges could reduce profitability.
- Potential: Adverse events or product recalls could damage the company's reputation.
- Ongoing: Dependence on the Chinese market exposes the company to economic and political risks.
Growth Opportunities
- Expansion into New Therapeutic Areas: China Shineway Pharmaceutical can capitalize on the growing demand for specialized medicines by expanding its product offerings into new therapeutic areas such as oncology and immunology. These areas represent significant market opportunities with increasing prevalence of related diseases. Investing in research and development to create innovative TCM-based treatments for these conditions could drive substantial revenue growth. The global oncology market is projected to reach $286 billion by 2030, presenting a lucrative target for expansion.
- Increased Investment in Research and Development: A greater focus on R&D will allow China Shineway Pharmaceutical to develop novel drug formulations and improve existing products. This can lead to increased market share and higher profit margins. Government support for pharmaceutical innovation in China provides a favorable environment for R&D investments. By allocating more resources to research, the company can create a pipeline of new products that address unmet medical needs and drive long-term growth.
- Geographic Expansion within China: Expanding its distribution network to cover more regions within China can significantly increase China Shineway Pharmaceutical's market reach. Focusing on Tier 2 and Tier 3 cities, where healthcare access is still developing, presents a significant opportunity. Establishing partnerships with local hospitals and pharmacies can facilitate market entry and build brand recognition. The Chinese pharmaceutical market is highly fragmented, offering ample opportunities for expansion.
- Leveraging E-commerce Platforms: Utilizing e-commerce platforms to sell its products directly to consumers can enhance China Shineway Pharmaceutical's sales and marketing efforts. Online channels provide a cost-effective way to reach a wider audience and improve customer engagement. Investing in digital marketing and building a strong online presence can drive significant revenue growth. The e-commerce market in China is one of the largest in the world, offering a vast potential customer base.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies or acquiring smaller players can accelerate China Shineway Pharmaceutical's growth. Collaborations can provide access to new technologies, markets, and distribution channels. Acquisitions can expand the company's product portfolio and increase its market share. Identifying synergistic opportunities and executing strategic deals can create significant value for shareholders.
Opportunities
- Expansion into new therapeutic areas such as oncology and immunology.
- Increased investment in research and development to create innovative products.
- Geographic expansion within China, focusing on Tier 2 and Tier 3 cities.
- Leveraging e-commerce platforms to reach a wider audience.
Threats
- Competition from other pharmaceutical companies.
- Pricing pressures and reimbursement challenges.
- Changes in government regulations and policies.
- Potential for adverse events or product recalls.
Competitive Advantages
- Established Brand: China Shineway Pharmaceutical has built a recognized brand in the Chinese medicine market.
- Product Diversification: The company offers a wide range of products across various therapeutic areas.
- Distribution Network: The company has an established distribution network in China and Hong Kong.
- Research and Development Capabilities: The company invests in R&D to develop new and innovative products.
About CSWYF
China Shineway Pharmaceutical Group Limited, established in 2004 and headquartered in Shijiazhuang, China, is an investment holding company specializing in the research, development, manufacture, and trade of Chinese medicines. As a subsidiary of Forway Investment Limited, the company plays a significant role in the production and distribution of both modern and traditional Chinese medicine formulations. Its product portfolio includes soft capsules, granules, and injections of modern Chinese medicines, as well as TCM (Traditional Chinese Medicine) Formula Granules. These products cater to a wide range of therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. Shineway Pharmaceutical's commitment to both modern and traditional approaches allows it to address a broad spectrum of healthcare needs within its primary markets of China and Hong Kong. The company also engages in the trade of agricultural products, diversifying its business interests. Through continuous research and development, China Shineway Pharmaceutical aims to innovate and improve its product offerings, maintaining a competitive edge in the dynamic pharmaceutical market. The company's integrated approach, from research to distribution, enables it to maintain quality control and ensure the efficacy of its medicines.
What They Do
- Researches and develops Chinese medicines.
- Manufactures modern Chinese medicines in various forms (soft capsules, granules, injections).
- Produces TCM (Traditional Chinese Medicine) Formula Granules.
- Trades Chinese medicines in the People's Republic of China and Hong Kong.
- Offers products for cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology therapeutic areas.
- Trades in agricultural products.
Business Model
- Develops and manufactures a range of Chinese medicines, both modern and traditional.
- Sells its products through distributors and directly to hospitals and pharmacies.
- Generates revenue from the sale of pharmaceutical products and agricultural products.
Industry Context
China Shineway Pharmaceutical Group Limited operates within the specialty and generic drug manufacturing industry, a segment experiencing growth driven by increasing healthcare expenditure and demand for affordable medicines. The Chinese pharmaceutical market is characterized by a blend of traditional Chinese medicine and modern pharmaceuticals. Key competitors include AIHLF, CCHWF, EBRCZ, IVEVF, and KDGTF. The industry faces regulatory scrutiny and pricing pressures, but also benefits from government support for local pharmaceutical companies. China's aging population and rising chronic disease rates are expected to further fuel demand for pharmaceutical products.
Key Customers
- Hospitals and clinics in China and Hong Kong.
- Pharmacies and drug stores.
- Patients seeking Chinese medicine treatments.
- Distributors of pharmaceutical products.
Financials
Chart & Info
China Shineway Pharmaceutical Group Limited (CSWYF) stock price: Price data unavailable
Latest News
No recent news available for CSWYF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CSWYF.
Price Targets
Wall Street price target analysis for CSWYF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CSWYF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Zhenjiang Li
CEO
Zhenjiang Li is the CEO of China Shineway Pharmaceutical Group Limited, leading a workforce of 3220 employees. His background includes extensive experience in the pharmaceutical industry, with a focus on traditional Chinese medicine. He has a strong understanding of the Chinese healthcare market and regulatory environment. Prior to his role at China Shineway Pharmaceutical, he held various leadership positions in pharmaceutical manufacturing and distribution companies.
Track Record: Under Zhenjiang Li's leadership, China Shineway Pharmaceutical has maintained a strong market position and achieved consistent profitability. He has overseen the expansion of the company's product portfolio and the strengthening of its distribution network. His strategic decisions have contributed to the company's growth and success in the competitive pharmaceutical market.
CSWYF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that China Shineway Pharmaceutical Group Limited may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting or may not be current in their disclosures. Investing in companies on the OTC Other tier carries higher risks compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of stringent listing standards and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure may hinder comprehensive analysis.
- Lower liquidity can lead to price volatility and difficulty in trading shares.
- OTC Other tier companies face less regulatory oversight, increasing the risk of fraud or mismanagement.
- The company's financial health and operations may not be as transparent as those of exchange-listed companies.
- Potential for delisting or suspension of trading due to non-compliance with OTC market regulations.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Analyze the company's business model and competitive landscape.
- Evaluate the company's compliance with relevant regulations.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- The company has been in operation since 2004.
- It has a substantial number of employees (3220).
- The company has a positive profit margin of 24.8%.
- The company has a dividend yield of 5.52%.
- The company's products are used in various therapeutic areas.
Common Questions About CSWYF
What does China Shineway Pharmaceutical Group Limited do?
China Shineway Pharmaceutical Group Limited is engaged in the research, development, manufacture, and trade of Chinese medicines, including both modern formulations and traditional TCM granules. The company's products target a wide range of therapeutic areas, such as cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. Operating primarily in China and Hong Kong, China Shineway Pharmaceutical aims to provide effective healthcare solutions through its diverse product portfolio, contributing to the health and well-being of its consumers.
What do analysts say about CSWYF stock?
As of 2026-03-16, formal analyst ratings for China Shineway Pharmaceutical Group Limited (CSWYF) are limited due to its OTC listing. However, the company's financial metrics, including a P/E ratio of 7.38 and a profit margin of 24.8%, suggest potential value. Investors should conduct their own due diligence, considering the company's growth prospects, competitive landscape, and regulatory environment. The dividend yield of 5.52% may be an attractive factor for income-seeking investors.
What are the main risks for CSWYF?
China Shineway Pharmaceutical Group Limited faces several risks, including regulatory changes in the pharmaceutical industry, competition from other drug manufacturers, and pricing pressures. As an OTC-listed company, CSWYF also faces risks related to liquidity and transparency. Dependence on the Chinese market exposes the company to economic and political risks. Investors should carefully consider these factors before investing in CSWYF.
How does China Shineway Pharmaceutical Group Limited navigate regulatory approval processes?
China Shineway Pharmaceutical Group Limited operates primarily within the regulatory framework of the People's Republic of China and Hong Kong. The company must comply with the regulations set forth by the China Food and Drug Administration (CFDA) and other relevant regulatory bodies. Navigating these processes involves rigorous testing, clinical trials, and documentation to ensure the safety and efficacy of its pharmaceutical products. The company's ability to successfully obtain and maintain regulatory approvals is crucial for its continued operation and growth within the Chinese pharmaceutical market.
What are the key growth opportunities for CSWYF in healthcare?
China Shineway Pharmaceutical Group Limited has several key growth opportunities within the healthcare sector. These include expanding its product offerings into new therapeutic areas such as oncology and immunology, increasing investment in research and development to create innovative products, and leveraging e-commerce platforms to reach a wider audience. Additionally, the company can pursue geographic expansion within China, focusing on Tier 2 and Tier 3 cities where healthcare access is still developing. Strategic partnerships and acquisitions can also accelerate growth by providing access to new technologies, markets, and distribution channels.
What are the key factors to evaluate for CSWYF?
China Shineway Pharmaceutical Group Limited (CSWYF) currently holds an AI score of 51/100, indicating moderate score. Key strength: Established presence in the Chinese medicine market.. Primary risk to monitor: Potential: Regulatory changes in the pharmaceutical industry could impact the company's operations.. This is not financial advice.
How frequently does CSWYF data refresh on this page?
CSWYF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CSWYF's recent stock price performance?
Recent price movement in China Shineway Pharmaceutical Group Limited (CSWYF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established presence in the Chinese medicine market.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- Analyst coverage may be limited due to OTC listing.